Professor, Pediatrics, Children's Hospital, Harvard Medical School
Pediatric Hematology & Oncology
Dr. Alan D. Michelson, MD
|
|
Give Review
Doctor Alan D. Michelson, MD is an expert in the field of Pediatric Hematology & Oncology. Alan D. Michelson, MD is also published. He has 67 publications published. The lastest publication: "Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.'
Publications
- Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
- Platelet-rich plasma stimulated by pulse electric fields: Platelet activation, procoagulant markers, growth factor release and Cell proliferation.
- New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors.
- Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia.
- Platelet activation using electric pulse stimulation: Growth factor profile and clinical implications.
- Do immature platelet levels in chest pain patients presenting to the emergency department aid in the diagnosis of acute coronary syndrome?
- The aryl hydrocarbon receptor directs hematopoietic progenitor Cell expansion and differentiation.
- Platelet Activation and Inhibition iN Sickle cell disease (PAINS) study.
- Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-me...
- Modified diadenosine tetraphosphates with dual specificity for P2Y(1) and P2Y(12) are potent antagonists of ADP-induced platelet activation.
- Granule exocytosis is required for platelet spreading: differential sorting of α-granules expressing VAMP-7.
- A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetic...
- Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular Disease.
- The influence of intermittent hypoxemia on platelet activation in obese patients with obstructive sleep apnea.
- Hormonal contraception and thrombotic risk: a multidisciplinary approach.
- Advances in antiplatelet therapy.
- The Human Endogenous Circadian System Causes Greatest Platelet Activation during the Biological Morning Independent of Behaviors.
- The Platelet Activity After Clopidogrel Termination (PACT) study.
- Thrombophilia and pediatric stroke.
- Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors.
- Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac c...
- New P2Y12 antagonists.
- The platelet hyporeactivity of extremely low birth weight neonates is age-dependent.
- Methods for the measurement of platelet function.
- Platelet antistaphylococcal responses occur through P2X1 and P2Y12 receptor-induced activation and kinocidin release.
- Antiplatelet therapy and platelet function testing.
- Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention.
- Investigating the mechanisms of hyporesponse to antiplatelet approaches.
- Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes.
- The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention.
- Assessing the current role of platelet function testing.
- Antiplatelet therapy and platelet function testing. Introduction.
- P2Y12 antagonism: promises and challenges.
- Effect of adenosine A2 receptor stimulation on platelet activation-aggregation: differences between canine and human models.
- Platelet function monitoring in patients with coronary artery Disease.
- Cystic fibrosis heterozygotes do not have increased platelet activation.
- Measuring antiplatelet drug effects in the laboratory.
- Current options in platelet function testing.
- Arterial ischemic stroke in children: baby steps.
- Frequency of aspirin resistance in a community hospital.
- Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-pati...
- The inflammatory role of platelets in cystic fibrosis.
- Therapeutic goals for effective platelet inhibition: a consensus document.
- Antiplatelet therapy in children.
- Platelet activation and progression to complications.
- Noncompliance in cardiovascular clinical trials.
- Clopidogrel linking evaluation of platelet response variability to mechanism of action.
- Platelet activation in cystic fibrosis.
- Aspirin resistance and its implications in clinical practice.
- Platelet function testing in cardiovascular Diseases.
- Application of flow cytometry to platelet Disorders.
- Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
- Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization.
- Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation.
- Spirochete-platelet attachment and thrombocytopenia in murine relapsing fever borreliosis.
- Neonatal platelet function.
- Whole blood analysis of leukocyte-platelet aggregates.
- Two novel mutations in the alpha IIb calcium-binding domains identify hydrophobic regions essential for alpha IIbbeta 3 biogenesis.
- Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
- The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial Cell adhesion than is thrombin.
- The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab the...
- Immunophenotypic analysis of platelets.
- Platelets: New Understanding of Platelet Glycoproteins and Their Role in Disease.
- P2Y12 Receptor Blockade Augments Glycoprotein IIb-IIIa Antagonist Inhibition of Platelet Activation, Aggregation, and Procoagulant Activity.
- Point-of-care assessment of platelet reactivity in the emergency department may facilitate rapid rule-out of acute coronary syndromes: a prospective cohort pilot feasi...
- Antiplatelet Activity, P2Y1 and P2Y12 Inhibition, and Metabolism in Plasma of Stereoisomers of Diadenosine 5',5'â³-P1,P4-dithio-P2,P3-chloromethylenetetraphosphate.
Schools
The Med School University Of Adelaide
Alfred Hospital Australia
Royal Children39s Hospital Austral
Children39s Hospital Boston
Conditions Treated
- Anemia
- Coagulation Disorders (incl. Hemophilia)
- Immune Thrombocytopenic Purpura (ITP)
- Neutropenia
- View All
Doctors Specialties
- Pediatric Hematology
- Oncology
Accepted Insurances
Education
-
Brigham and Women's Hospital -
The University of Adelaide Faculty of Health Sciences
Hospital
-
Boston Children's Hospital -
Brigham and Women's Hospital -
Dana-Farber Cancer Institute
Helpful Reviews
Similar Doctors
|
|
Kapil Saxena, MB
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel P. Kronish, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Samuel E. Lux IV, MD
This Doctor is OpenDoctor Recommended.
|